Avidity Biosciences, Inc. — Investor Relations & Filings

Avidity Biosciences, Inc. is a biopharmaceutical company developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs). The company's proprietary AOC platform combines the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide-based therapies. This approach is designed to overcome challenges in drug delivery by enabling targeted transport of RNA therapeutics to specific cells and tissues, such as muscle, that were previously inaccessible. Avidity's pipeline is initially focused on developing treatments for rare muscle diseases, with the objective of addressing the underlying genetic drivers of these conditions and expanding into other therapeutic areas.